Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dasminapant - Ascentage Pharma

Next Previous
Drug Profile

Dasminapant - Ascentage Pharma

Alternative Names: APG-1387; SM-1387

Latest Information Update: 26 Jan 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ascentage Pharma
  • Developer Ascentage Pharma; Southern Medical University
  • Class Antineoplastics; Antivirals; Small molecules
  • Mechanism of Action Inhibitor of apoptosis protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hepatitis B
  • Phase I/II Adenocarcinoma; Solid tumours
  • No development reported Haematological malignancies; Lymphoma

Most Recent Events

  • 10 Dec 2024 Ascentage Pharma terminates a phase I/II trial in Adenocarcinoma (Combination therapy, Late-stage disease, Second-line therapy or greater) in China (IV) due to company strategy (NCT04643405)
  • 30 Nov 2024 Ascentage Pharma terminates a phase I/II trial in Solid tumours (Combination therapy, Second-line therapy or greater, Late-stage disease) in China (IV) due to company strategy (NCT04284488)
  • 28 Nov 2024 No recent reports of development identified for phase-I development in Haematological-malignancies(Late-stage disease) in USA (IV, Infusion)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top